Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension[J]. Cell, 2001, 104(4):545. [2] Hsu MH, Savas ü , Griffin KJ, et al. Human cytochrome p450 family 4 enzymes:function, genetic variation and regulation[J]. Drug Metabolism Reviews, 2007, 39(2-3):515-538. [3] Hirani V, Yarovoy A, Kozeska A, et al. Expression of CYP4F2 in human liver and kidney:assessment using targeted peptide antibodies[J]. Arch Biochem Biophy, 2008, 478(1):59-68. [4] Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production[J]. Physiological Genomics, 2007, 30(1):74-81. [5] Wu CC, Gupta T, Garcia V, et al. 20-HETE and blood Pressure regu-lation:clinical implications[J]. Cardiol Rev, 2013:1538-4683. [6] Roman RJ. P-450 metabolites of arachidonic acid in the control of car-diovascular function[J]. Physiol Revi, 2002, 82(1):131-185. [7] Sodhi K, Wu CC, Cheng J, et al. CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid-and angiotensin II-dependent[J]. Hypertension, 2010, 56(5):871-878. [8] 赵钰岚, 许传莲.血管紧张素转换酶的结构功能及相关抑制剂[J].生物工程学报, 2008, 24(2):171-176. [9] Deponte M. GFP tagging sheds light on protein translocation:implications for key methods in cell biology[J]. Cellular and Molecular Life Sciences, 2012, 69(7):1025-1033. [10] Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose[J]. Blood, 2008, 111(8):4106-4112. [11] 范春红, 何青芳, 俞敏, 等. CYP4F2 基因多态性与原发性高血压易感性的相关性研究[J].浙江医学, 2011, 33(12):1732-1734. [12] Oyekan AO, McAward K, Conetta J, et al. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension[J]. Ame J Physiol, 1999, 276(3):R766-R775.